A new hexavalent vaccine for use in children aged 6 weeks through 4 years has been approved by the FDA to prevent diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B.
Morbidity & Mortality Weekly Report
Original Article: Licensure of a New Hexavalent Vaccine for Use in Infants